HepaRegeniX is backed by experienced life science investors, including Vesalius Biocapital IV, Novo Holdings A/S, Boehringer Ingelheim Venture Fund (BIVF), Coparion, High-Tech Gründerfonds, Ascenion ...

To participate, please dial one of the following numbers and ask to join the Verona Pharma call: A live webcast will be available on the Events and Presentations link on the Investors page of the ...

Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target ...

Linda brings more than 20 years of financial, operational and executive leadership success at innovative life science companies,” said Matt Patterson, Chairman of Remix Therapeutics Board of Directors ...

Nampa, April 15, 2025 (GLOBE NEWSWIRE) -- Best Diabetes Supplement of 2025: Learn How GlucoRedi Sets a New Benchmark in Wellness Industry Content Promoted By Branding EX Solution pvt ltd ( ...

Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) ...

Native Hydrate by Native Path is quickly gaining attention as a zero-sugar electrolyte and BCAA drink mix designed to help people stay hydrated, recover faster, and fuel their muscles—without the ...

“Skye believes nimacimab shows potential both as a monotherapy and in combination with a GLP-1 targeted drug to address unmet needs in obesity with the potential to change weight loss standards of ...

New clinical data from the SYMON-I study to evaluate IL-6 in sepsis patients to be presented.

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform ™ drug optimization technology, announced that Randall ...

Vistin Pharma ASA (VISTN) will release its first quarter results on Friday 25th of April 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at ...

Pierluigi Paracchi, CEO Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, will present at “Montalcini Global Biotech Tour” in Doha, Qatar on April ...